New Beta Innovation Limited
NEWS
Summary
27 November, 2019

New Beta Innovation Canada Ltd.’s Facilities Compliant under Health Canada Drug Establishment Regulations

In February of this year, Health Canada auditors completed a rigorous 5-day on-site inspection of New Beta Innovation Canada Limited’s (NBI-CA) facility located in Burnaby, British Columbia. The results were positive with regulators giving NBI-CA a compliant rating. NBI-CA was also granted an initial Drug Establishment License (DEL) for the manufacture, packaging, testing, distribution and wholesale of veterinary pharmaceuticals. This license, valid from June 17, 2019 is a major milestone for NBI-CA towards building the capacity to bring its hemoglobin derived products to market.

NBI-CA is currently one of the only facilities of this size and capacity in Western Canada with the capability to make sterile liquid products as regulated by Good Manufacturing Practices (GMP). NBI-CA’s team has been working towards GMP compliance and becoming a fully operational commercial manufacturing facility since it obtained occupancy of the Burnaby facility in March 2017.

Health Canada conducts drug establishment inspections to ensure that products sold to Canadians meet strict guidelines for quality and safety, with the ultimate goal of preventing harm to the end-user. Some of the things that auditors look for include: sanitation, training, records, written procedures, storage, temperature control, ventilation and product testing to name a few. Auditors made several observations during the inspection that NBI-CA is currently addressing. A follow-up inspection is pending in 2020 to evaluate NBI-CA’s progress and corrective actions.


The upcoming plans of NBI-CA within North America include exploring an option to create a secondary upstream manufacturing facility in addition to our New Zealand Operations as well as filing a new animal drug application with the US FDA. NBI-CA is also in the process of developing its human drug, and has completed the first phase of a Healthy Volunteer Study to Evaluate Safety on the Use of YQ23 in the UK. A Health Canada compliant rating is essential as NBI-CA continues to make strides towards developing these novel treatments for disease.

NBI-CA has a highly qualified team who work collaboratively to achieve quality and regulatory compliance. With a relatively small workforce NBI-CA has achieved a lot, as noted by Health Canada auditors. The team is prepared and ready to meet several other milestones to achieve full GMP readiness according to not only Canadian, but also EU EMA and US FDA regulations.







References:

NBICA Inspection report card summary: https://www.drug-inspections.canada.ca/gmp/fullReportCard-en.html?lang=en&insNumber=71202

About Drug Inspections: https://www.canada.ca/en/health-canada/services/inspecting-monitoring-drug-health-products/drug-health-product-inspections/about-drug-inspections.html

Good Manufacturing Practices Inspection Policy: https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/good-manufacturing-practices/policies-standards/inspection-policy-canadian-drug-establishments.html

Good Manufacturing Practices: https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/good-manufacturing-practices.html

Good manufacturing practices guide for drug products (GUI-0001): https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/good-manufacturing-practices/guidance-documents/gmp-guidelines-0001/document.html#a1


1-2 March, 2018

Event Sponsor: ICPOEP 2018

sponsors the event of the University of Hong Kong Clinical Trials Centre (HKU-CTC) for the 4th International Conference on Phase 1 and Early Phase Clinical Trials (ICPOEP).

3-4 November, 2016

Event Sponsor: ICPOEP 2016

NBI sponsors the event of the University of Hong Kong Clinical Trials Centre (HKU-CTC) for the 3rd International Conference on Phase 1 and Early Phase Clinical Trials (ICPOEP).

11 July, 2016

NBI receives HK DOH approval to proceed with a Phase 1 Clinical Trial (First in Patient) of YQ23 in patients with advanced tumors.

21 March, 2016

YQ23 has been granted the Orphan Medicinal Product Designation by the EMA for the treatment of oesophageal cancer.

13 October, 2015

NBI receives UK MHRA approval to proceed with a Phase 1 Clinical Trial (First in human) of YQ23 in healthy volunteers.

19 November, 2014

YQ23 has been granted the Orphan Medicinal Product Designation by the EMA for the treatment of hepatocellular carcinoma.

× We use page tagging techniques and cookies to improve the site, provide services to you, and customize your browsing experience. By continuing to browse the site you are agreeing to accept our use of cookies